These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 23636866

  • 1. Urethral dilatation: Is there any benefit over cystoscopy and distension? A randomized trial in women with overactive bladder symptoms.
    Basu M, Khullar V, Duckett J.
    Neurourol Urodyn; 2014 Mar; 33(3):283-8. PubMed ID: 23636866
    [Abstract] [Full Text] [Related]

  • 2. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C.
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [Abstract] [Full Text] [Related]

  • 3. Association of symptoms with urodynamic findings in men with overactive bladder syndrome.
    Al-Zahrani AA, Gajewski JB.
    BJU Int; 2012 Dec; 110(11 Pt C):E891-5. PubMed ID: 22928556
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE, Morrow JD, Kraus SR, Creanga D, Bavendam T.
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [Abstract] [Full Text] [Related]

  • 5. The effect of urethral dilatation on pressure flow studies in women with voiding dysfunction and overactive bladder.
    Basu M, Duckett J.
    Int Urogynecol J Pelvic Floor Dysfunct; 2009 Sep; 20(9):1073-7. PubMed ID: 19444366
    [Abstract] [Full Text] [Related]

  • 6. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C, Schneider T, Haab F, Sun F, Whelan L, Scholfield D, Dragon E, Mangan E.
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [Abstract] [Full Text] [Related]

  • 7. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
    Noblett K, Siegel S, Mangel J, Griebling TL, Sutherland SE, Bird ET, Comiter C, Culkin D, Bennett J, Zylstra S, Kan F, Berg KC.
    Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
    [Abstract] [Full Text] [Related]

  • 8. Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome.
    Chung SD, Liao CH, Chen YC, Kuo HC.
    Neurourol Urodyn; 2011 Sep; 30(7):1300-4. PubMed ID: 21560153
    [Abstract] [Full Text] [Related]

  • 9. A prospective assessment of overactive bladder symptoms in a cohort of elderly women who underwent transvaginal surgery for advanced pelvic organ prolapse.
    Foster RT, Barber MD, Parasio MF, Walters MD, Weidner AC, Amundsen CL.
    Am J Obstet Gynecol; 2007 Jul; 197(1):82.e1-4. PubMed ID: 17618768
    [Abstract] [Full Text] [Related]

  • 10. Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms.
    Abdel-Fattah M, Chapple C, Guerrero K, Dixon S, Cotterill N, Ward K, Hashim H, Monga A, Brown K, Drake MJ, Gammie A, Mostafa A, Bladder Health UK, Breeman S, Cooper D, MacLennan G, Norrie J.
    Trials; 2021 Oct 26; 22(1):745. PubMed ID: 34702331
    [Abstract] [Full Text] [Related]

  • 11. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.
    Curr Med Res Opin; 2009 Sep 26; 25(9):2159-65. PubMed ID: 19601704
    [Abstract] [Full Text] [Related]

  • 12. Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome.
    Hsiao SM, Lin HH, Kuo HC.
    Neurourol Urodyn; 2014 Mar 26; 33(3):331-4. PubMed ID: 23494586
    [Abstract] [Full Text] [Related]

  • 13. Urethral injection therapy: what is the mechanism of action?
    Klarskov N, Lose G.
    Neurourol Urodyn; 2008 Mar 26; 27(8):789-92. PubMed ID: 18642372
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness and safety of acupuncture for elderly overactive bladder population in Hong Kong: study protocol for a randomized controlled trial.
    Chan YT, Zhang HW, Guo YQ, Chan TNH, Kwan YK, Lee CK, Ngan K, Lin ZX.
    Trials; 2018 Jul 13; 19(1):376. PubMed ID: 30005707
    [Abstract] [Full Text] [Related]

  • 15. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
    Kubota Y, Kojima Y, Shibata Y, Imura M, Kohri K, Sasaki S.
    Neurourol Urodyn; 2011 Sep 13; 30(7):1309-14. PubMed ID: 21560155
    [Abstract] [Full Text] [Related]

  • 16. Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence.
    van Gool JD, de Jong TP, Winkler-Seinstra P, Tamminen-Möbius T, Lax H, Hirche H, Nijman RJ, Hjälmås K, Jodal U, Bachmann H, Hoebeke P, Walle JV, Misselwitz J, John U, Bael A, European Bladder Dysfunction Study (EU BMH1-CT94-1006).
    Neurourol Urodyn; 2014 Jun 13; 33(5):482-7. PubMed ID: 23775924
    [Abstract] [Full Text] [Related]

  • 17. Duloxetine compared with placebo for treating women with symptoms of overactive bladder.
    Steers WD, Herschorn S, Kreder KJ, Moore K, Strohbehn K, Yalcin I, Bump RC, Duloxetine OAB Study Group.
    BJU Int; 2007 Aug 13; 100(2):337-45. PubMed ID: 17511767
    [Abstract] [Full Text] [Related]

  • 18. Pre-operative opening detrusor pressure is predictive of detrusor overactivity following TVT in patients with pre-operative mixed urinary incontinence.
    Panayi DC, Duckett J, Digesu GA, Camarata M, Basu M, Khullar V.
    Neurourol Urodyn; 2009 Aug 13; 28(1):82-5. PubMed ID: 19089898
    [Abstract] [Full Text] [Related]

  • 19. Correlation between cystometric volumes, ATP release, and pH in women with overactive bladder versus controls.
    Cheng Y, Mansfield KJ, Allen W, Millard RJ, Burcher E, Moore KH.
    Neurourol Urodyn; 2013 Sep 13; 32(7):969-73. PubMed ID: 23129360
    [Abstract] [Full Text] [Related]

  • 20. Comparison of biofeedback therapy in children with treatment-refractory dysfunctional voiding and overactive bladder.
    Tugtepe H, Thomas DT, Ergun R, Abdullayev T, Kastarli C, Kaynak A, Dagli TE.
    Urology; 2015 Apr 13; 85(4):900-4. PubMed ID: 25669732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.